Concerned about being at risk of RSV? If you are 60+ years old, you may be eligible to participate in the Respiratory Syncytial Virus clinical trial that’s studying potential new vaccines.
Respiratory Syncytial Virus Clinical Trial
What is respiratory syncytial virus (RSV)?
RSV is a very common, contagious virus that causes infections of the respiratory tract. RSV begins with cold-like symptoms but can spread to the lungs. RSV affects people of all ages, but in adults RSV infections are generally minor. However, older adults can sometimes have serious complications, including inflammation of the lungs or pneumonia.
These clinical trials are important as there is currently no vaccine for RSV. Participants will help us in our fight to prevent RSV in older adults in the future.
What are the RSV studies?
The RSV studies are looking at investigational vaccines against respiratory syncytial virus (RSV). Doctors in local research studies are looking at potential new investigational vaccines for RSV. They are evaluating how safe investigation vaccines are and whether they can improve a patient’s quality of life. These investigational vaccines can only be given to patients as part of clinical research studies. We are looking for older adults to take part in the studies.
People who qualify may receive compensation for time and travel, investigational study interventions at no cost, and care from study doctors at no cost. Some people participate in research studies to contribute to medical science and help doctors find other ways to help patients.
Those who qualify may receive:
- Payment of up to $440
- Study-related care from local doctors at no cost
- Study medication at no cost
- Compensation for time and travel
There is no obligation, so see if you may qualify now.